These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 28359815)

  • 1. Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin.
    Du H; Liu M; Yu A; Ji J; Zhai G
    Int J Pharm; 2017 May; 523(1):427-438. PubMed ID: 28359815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
    Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
    Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced delivery of doxorubicin to the liver through self-assembled nanoparticles formed via conjugation of glycyrrhetinic acid to the hydroxyl group of hyaluronic acid.
    Wang X; Gu X; Wang H; Yang J; Mao S
    Carbohydr Polym; 2018 Sep; 195():170-179. PubMed ID: 29804965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
    Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
    Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma.
    Xia Y; Zhong J; Zhao M; Tang Y; Han N; Hua L; Xu T; Wang C; Zhu B
    Drug Deliv; 2019 Dec; 26(1):1-11. PubMed ID: 31928356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Codelivery of Doxorubicin and shAkt1 by Poly(ethylenimine)-Glycyrrhetinic Acid Nanoparticles To Induce Autophagy-Mediated Liver Cancer Combination Therapy.
    Wang FZ; Xing L; Tang ZH; Lu JJ; Cui PF; Qiao JB; Jiang L; Jiang HL; Zong L
    Mol Pharm; 2016 Apr; 13(4):1298-307. PubMed ID: 26894988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Reactive Oxygen Species Generation by Mitochondria Targeting of Anticancer Drug To Overcome Tumor Multidrug Resistance.
    Liu Y; Zhou Z; Lin X; Xiong X; Zhou R; Zhou M; Huang Y
    Biomacromolecules; 2019 Oct; 20(10):3755-3766. PubMed ID: 31465208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular self-disassemble polysaccharide nanoassembly for multi-factors tumor drug resistance modulation of doxorubicin.
    Xiong H; Ni J; Jiang Z; Tian F; Zhou J; Yao J
    Biomater Sci; 2018 Aug; 6(9):2527-2540. PubMed ID: 30105340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin modified graphene oxide for pH-sensitive sustained release of doxorubicin hydrochloride.
    Zhang B; Yang X; Wang Y; Zhai G
    Mater Sci Eng C Mater Biol Appl; 2017 Jun; 75():198-206. PubMed ID: 28415455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
    Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
    Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer.
    Yang T; Lan Y; Cao M; Ma X; Cao A; Sun Y; Yang J; Li L; Liu Y
    Colloids Surf B Biointerfaces; 2019 Mar; 175():106-115. PubMed ID: 30529816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
    Chen F; Zhang J; He Y; Fang X; Wang Y; Chen M
    Biomater Sci; 2016 Jan; 4(1):167-82. PubMed ID: 26484363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surfactin-based nanoparticles loaded with doxorubicin to overcome multidrug resistance in cancers.
    Huang W; Lang Y; Hakeem A; Lei Y; Gan L; Yang X
    Int J Nanomedicine; 2018; 13():1723-1736. PubMed ID: 29606866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
    Tian Q; Zhang CN; Wang XH; Wang W; Huang W; Cha RT; Wang CH; Yuan Z; Liu M; Wan HY; Tang H
    Biomaterials; 2010 Jun; 31(17):4748-56. PubMed ID: 20303163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier.
    Lu J; Zhao W; Huang Y; Liu H; Marquez R; Gibbs RB; Li J; Venkataramanan R; Xu L; Li S; Li S
    Mol Pharm; 2014 Nov; 11(11):4164-78. PubMed ID: 25265550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination chemotherapy of doxorubicin, all-trans retinoic acid and low molecular weight heparin based on self-assembled multi-functional polymeric nanoparticles.
    Zhang T; Xiong H; Dahmani FZ; Sun L; Li Y; Yao L; Zhou J; Yao J
    Nanotechnology; 2015 Apr; 26(14):145101. PubMed ID: 25771790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
    Li W; Yi X; Liu X; Zhang Z; Fu Y; Gong T
    J Control Release; 2016 Mar; 225():170-82. PubMed ID: 26826304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
    He Y; Su Z; Xue L; Xu H; Zhang C
    J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin.
    Guo H; Zhang D; Li T; Li C; Guo Y; Liu G; Hao L; Shen J; Qi L; Liu X; Luan J; Zhang Q
    J Pharm Sci; 2014 Mar; 103(3):987-93. PubMed ID: 24549734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.